Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
300
datasets available to search
ShareScore release 0.9.0
Dataset results
300 results for “aromatase”
Epigenetic regulation of gonadal and brain aromatase expression in a cichlid fish with environmental sex determination
GEO Series GSE135681. blank sample; Pelvicachromis pulcher. 173 samples. Type: Methylation profiling by high throughput sequencing.
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients
GEO Series GSE126870. Homo sapiens. 178 samples. Type: Expression profiling by array.
FOXA1 Shapes the Chromatin State of ILC and Drives Differential Response to Aromatase Inhibitors and Tamoxifen [HiChIP-seq]
GEO Series GSE152366. Homo sapiens. 4 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences [HumanMethylationE
GEO Series GSE274415. Homo sapiens. 176 samples. Type: Methylation profiling by genome tiling array.
Data from: Differential sensitivity to in vitro inhibition of cytochrome P450 aromatase (CYP19) activity among 18 freshwater fishes
There is significant concern regarding potential impairment of fish reproduction associated with endocrine disrupting chemicals. Aromatase (CYP19) is a steroidogenic enzyme involved in the conversion of androgens to estrogens. Inhibition of aromatase by chemicals can result in reduced concentrations of estrogens leading to adverse reproductive effects. These effects have been extensively investigated in a small number of laboratory model fishes, such as fathead minnow (Pimephales promelas), Japanese medaka (Oryzias latipes), and zebrafish (Danio rerio). But, differences in sensitivity among species is largely unknown. Therefore, this study took a first step towards understanding potential differences in sensitivity to aromatase inhibitors among fishes. Specifically, a standard in vitro aromatase inhibition assay using subcellular fractions of whole tissue homogenates was used to evaluate the potential sensitivity of eighteen phylogenetically diverse species of freshwater fish to the nonsteroidal aromatase inhibitor fadrozole. Sensitivity to fadrozole ranged by more than 52-fold among these species. Five species were further investigated for sensitivity to up to four additional nonsteroidal aromatase inhibitors, letrozole, imazalil, prochloraz, and propiconazole. Potencies of each of these chemicals relative to fadrozole ranged by up to two orders of magnitude among the five species. Fathead minnow, Japanese medaka, and zebrafish were among the least sensitive to all the investigated chemicals; therefore, ecological risks of aromatase inhibitors derived from these species might not be adequately protective of more sensitive native fishes. This information could guide more objective ecological risk assessments of native fishes to chemicals that inhibit aromatase.
Data from: Higher insulin resistance & adiposity in post-menopausal women with breast cancer treated with aromatase inhibitors
Context: Aromatase deficiency causes obesity and insulin resistance in aromatase knockout mice and humans with rare mutations of the aromatase gene (CYP19). Aromatase inhibitors are a commonly prescribed therapy in post-menopausal breast cancer. Objective: We hypothesized that aromatase inhibitors induce obesity and insulin resistance when used in treatment of breast cancer. Design: Case-control study Setting: University teaching hospital Participants: 20 post-menopausal breast cancer patients, treated with aromatase inhibitor and 20 age-matched controls. Main outcome measures: Primary outcome measure was insulin sensitivity index – Matsuda, derived from a 75g oral glucose tolerance test. Body composition was assessed by DEXA and subcutaneous adipose tissue biopsies obtained for assessment of mRNA transcript levels. Data are mean ± SEM (inhibitor vs controls). Results: Aromatase inhibitor therapy was associated with significantly lower insulin sensitivity (5.15 ± 0.45 vs. 6.80 ± 0.64, P = 0.041), higher peak insulin concentration following OGTT (693.4 ± 78.6 vs. 527.6 ± 85.5 pmol/L, P = 0.035), greater percentage body fat (38.4 ± 1.0 vs. 34.6 ± 1.3 %, P = 0.026), and higher plasma leptin concentration (23.5 ± 2.8 vs. 15.5 ± 2.3 ng/mL, P = 0.035). Conclusions: Women who received aromatase inhibitors for post-menopausal breast cancer have greater percentage body fat and insulin resistance compared to controls with no history of breast cancer.
A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors and Tamoxifen
ClinicalTrials.gov study NCT01223833. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)
ClinicalTrials.gov study NCT01908556. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Use of Aromatase Inhibitor Before Misoprostol in Medical Termination of Miscarriage
ClinicalTrials.gov study NCT07109947. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors
ClinicalTrials.gov study NCT03144037. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy
ClinicalTrials.gov study NCT00066339. IPD Sharing: Not stated. Countries: 1. Publications: 0.
SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer
ClinicalTrials.gov study NCT00272740. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors
ClinicalTrials.gov study NCT00738998. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Comparative Effectiveness of Acupuncture and Nonsteroidal Anti-inflammatory Drugs for the Management of Aromatase Inhibitor Induced Arthralgia Among Breast Cancer Survivors
ClinicalTrials.gov study NCT04511832. IPD Sharing: Not stated. Countries: 1. Publications: 0.
NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
ClinicalTrials.gov study NCT02689921. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Yoga for Aromatase Inhibitor-associated Joint Pain
ClinicalTrials.gov study NCT01951976. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
ClinicalTrials.gov study NCT00916162. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
ClinicalTrials.gov study NCT01758146. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Evaluating the Efficacy of Structured Exercise Interventions in Alleviating Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors: a Pilot Study Protocol
ClinicalTrials.gov study NCT06754293. IPD Sharing: NO. Countries: 1. Publications: 0.
Oral Aromatase Inhibitors Modify the Gut Microbiome
ClinicalTrials.gov study NCT05030038. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.